CLINICAL_TRIALS
trial_result
· 2022-10-07
Clinical Trial Update: Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa [Phase 1, Phase 2]
Summary
Phase 1/2 clinical trial of allogeneic ABCB5-positive stem cells for recessive dystrophic epidermolysis bullosa has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: RHEACELL GmbH & Co. KG | Conditions: Recessive Dystrophic Epidermolysis Bullosa | Phase 1, Phase 2 | Status: COMPLETED